OTC Markets OTCPK - Delayed Quote USD

Sanofi (SNYNF)

Compare

98.85

0.00

(0.00%)

As of 11 November at 3:00 pm GMT-5. Market open.

Key events

Advanced chart

Loading Chart for SNYNF

9/21 12:03 PM

DELL

Previous close 105.00
Open 105.00
Bid 97.87 x 46000
Ask 103.25 x 40000
Day's range 105.00 - 105.00
52-week range 88.34 - 119.65
Volume 550
Avg. Volume 21,781
Market cap (intra-day) 129.553B
Beta (5Y monthly) 0.44
PE ratio (TTM) 25.68
EPS (TTM) 3.85
Earnings date 30 Jan 2025
Forward dividend & yield 4.07 (4.11%)
Ex-dividend date 13 May 2024
1y target est --

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

www.sanofi.com

86,088